AGC Biologics, a Bothell, Washington-headquartered contract development and manufacturing organization of biologics, reports on its commercial supply agreement with MacroGenics, a Rockville, Maryland-based clinical-stage biopharmaceutical company, to manufacture margetuximab, a clinical-stage immune-optimized monoclonal antibody.

The companies formed the supply pact in late 2017. AGC Biologics has provided development and validation services for margetuximab since 2014, and says it plans to implement a transition to commercial supply services.

Margetuximab is an investigational product that targets the human epidermal growth factor receptor 2, or human epidermal growth factor receptor 2 (HER2). HER2 is expressed by tumor cells in breast, gastroesophageal, bladder, and other forms of solid-tumor cancers. Margetuximab has an Fc domain, which was engineered to enhance engagement and activation of the immune system.

Source: AGC Biologics